# Study of Tadalafil Once-a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia

> **NCT00384930** · PHASE2,PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 1058 (actual)

## Conditions studied

- Benign Prostatic Hyperplasia

## Interventions

- **DRUG:** tadalafil
- **DRUG:** tadalafil
- **DRUG:** tadalafil
- **DRUG:** tadalafil
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00384930
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08
- **Primary completion:** 2007-10
- **Final completion:** 2008-10
- **Target enrollment:** 1058 (ACTUAL)
- **Last updated:** 2009-09-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00384930

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00384930, "Study of Tadalafil Once-a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT00384930. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*